Back to search
Agitation in Participants With Dementia of the Alzheimer's Type
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Agitation in Participants With Dementia of the Alzheimer's Type trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Agitation in Participants With Dementia of the Alzheimer's Type trials you may qualify forThe goal of this clinical trial is to evaluate the safety and efficacy of EXV-802 and EXV-801 in treatment of agitation in participants with Alzheimer's Disease…
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a…
This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participants with Alz…
This study will be conducted to evaluate the efficacy, safety, tolerability, and pharmacokinetics of masupirdine compared to placebo for the treatment of agitat…
The purpose of this study is to evaluate the safety and tolerability of multiple ascending doses of elpipodect in participants with Alzheimer's Disease (AD) wit…
Participants with agitation secondary to dementia of the Alzheimer's type. The diagnosis of probable Alzheimer's disease (AD) will be based on the "2011 Diagnos…